What question did this study set out to answer?

This research aims to investigate the impacts of pre-biopsy MRI on prostate cancer diagnostics over a span of 13 years.

April 7, 2026Open Access

Trends and Patterns in Prostate Cancer Diagnostics During the Era of MRI Implementation – Real-world Evidence From a Population-based Study in the Stockholm Region, Sweden 2010–2023

JEJan Chandra EngelKarolinska Institutet BRBalram Rai MEMartin EklundKarolinska Institutet

Key Points

This research aims to investigate the impacts of pre-biopsy MRI on prostate cancer diagnostics over a span of 13 years.
Analyzed data from the Stockholm Prostate Cancer Diagnostics Register (2010–2023)
Included men aged ≥40 without prior prostate cancer
Examined trends in PSA testing and subsequent MRI/biopsy
Evaluated biopsy outcomes based on International Society of Urological Pathology (ISUP) grading
PSA testing rates remained stable, peaking at 84% in men aged 70–79 and ≥80 in 2023
MRI use before biopsy surged from 3% to 30%
Prostate biopsy rates dropped from 23% to 16%
Detection of ISUP GG ≥2 cancers more than doubled (RR: 2.12)
Significant reductions in benign biopsy and low-grade cancer detection were noted

Abstract

Implementation of pre-biopsy magnetic resonance imaging in prostate cancer diagnostics reduced unnecessary biopsies and low-grade cancer detection, while more than doubling the detection of clinically significant cancers, demonstrating improved precision of diagnostics at a population level. Pre-biopsy magnetic resonance imaging (MRI) is recommended in prostate cancer diagnostics, but its impact on testing patterns and diagnostic outcomes on a population-level remains unclear. Using the Stockholm Prostate Cancer Diagnostics Register, we conducted a population-based study of men aged ≥40 yr without prior prostate cancer during 2010–2023. We described the trends in prostate-specific antigen (PSA) testing, the proportion of men with PSA ≥3 ng/ml undergoing further testing (MRI and/or biopsy), and the distribution of biopsy outcomes. PSA testing was stable over time, with greater uptake observed in older men: in 2023, 14-yr prevalence was 76% in men aged 60–69 yr, and 84% in both those aged 70–79 and ≥80 yr. Among men with PSA ≥3 ng/ml, MRI within 1 yr increased from 3% in 2010 to 30% in 2023, while the proportion undergoing prostate biopsy declined from 23% to 16% (relative risk RR: 0.71; 95% confidence interval CI: 0.69–0.73). By 2023, 83% of biopsied men had a pre-biopsy MRI. Over the study period, biopsy outcomes improved: detection of International Society of Urological Pathology ISUP grade group GG ≥2 cancers more than doubled (RR: 2.12; 95% CI: 1.99–2.27), whereas both benign biopsies (RR: 0.66; 95% CI: 0.62–0.69) and ISUP GG 1 (RR: 0.61; 95% CI: 0.54–0.69) declined markedly. PSA testing remained prevalent, and pre-biopsy MRI use increased substantially. During this period, detection of significant cancer among biopsied men increased markedly while unnecessary biopsies and low-grade cancer findings decreased. This study provides real-world population-based data that are consistent with a trend toward increased precision in prostate cancer diagnostics in the era of MRI implementation.

KI fragen

Bookmark

View Full Paper

Cite This Study

Engel et al. (Sat,) studied this question.

synapsesocial.com/papers/69d49ecbb33cc4c35a227841 https://doi.org/https://doi.org/10.1016/j.euros.2026.03.015

KI fragen

Bookmark

View Full Paper